Status:
COMPLETED
Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch
Lead Sponsor:
UCB Pharma GmbH
Conditions:
Idiopathic Parkinson's Disease
Eligibility:
All Genders
Brief Summary
The study intends to collect data on gastrointestinal symptoms (swallowing disorders, heartburn, feeling of fullness, nausea, vomiting, abdominal pain, diarrhea) and on patient satisfaction under ever...
Detailed Description
Routine treatment as per approved label in Europe in accordance with the terms of the local marketing authorization for Neupro®.
Eligibility Criteria
Inclusion
- The decision to prescribe Neupro® must have been made by the physician before and independently of his/her decision to include the patient in the study
- The patient's treatment must be in accordance with the terms of the local marketing authorization (MA) for Neupro®
- The patient must have a diagnosis of Idiopathic Parkinson's disease
- The patient must have signed the Consent form regarding study information, data transfer and use
- Patient suffering from gastrointestinal symptoms while being treated with oral Parkinson's medication
Exclusion
- Not applicable
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT01159691
Start Date
June 1 2010
End Date
March 1 2012
Last Update
May 21 2013
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
02
Berlin, Germany
2
24
Bochum, Germany
3
38
Buchholz, Germany
4
7
Cologne, Germany